Published in Am J Cancer Res on April 03, 2013
Mast cells as a potential prognostic marker in prostate cancer. Dis Markers (2013) 0.84
Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer. Am J Cancer Res (2014) 0.81
Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila) (2014) 0.79
Racial disparities in prostate cancer: a molecular perspective. Front Biosci (Landmark Ed) (2017) 0.75
Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore) (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Prostate cancer epidemiology. Lancet (2003) 6.30
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin (2007) 5.67
Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst (2008) 5.64
Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst (1996) 4.66
Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control (2007) 4.61
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer (1991) 3.14
CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet (2002) 2.90
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst (1998) 2.67
Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst (1986) 2.27
A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med (2007) 2.20
Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res (1997) 2.18
The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res (2009) 1.90
Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem (1999) 1.89
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest (1993) 1.88
A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol (2006) 1.86
Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev (2007) 1.85
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res (1994) 1.85
The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res (1995) 1.84
Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev (2005) 1.80
Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet (2012) 1.78
5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet (1992) 1.77
Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis (2009) 1.75
Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst (2000) 1.72
Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res (2010) 1.71
A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res (2000) 1.70
Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet (2005) 1.67
Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol (2003) 1.61
Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.60
Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet (2012) 1.59
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer (2002) 1.58
Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol (1999) 1.58
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.57
Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr (2009) 1.57
Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev (2005) 1.55
XRCC1 genetic polymorphism Arg399Gln and prostate cancer risk: a meta-analysis. Urology (2009) 1.53
Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.51
Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA (1987) 1.44
Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev (1996) 1.44
The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol (2006) 1.43
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol (2008) 1.43
Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer (2003) 1.42
Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab (2006) 1.40
Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res (2000) 1.38
Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet (1999) 1.37
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res (2003) 1.37
Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev (2005) 1.37
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res (2010) 1.30
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.29
Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer (2009) 1.28
Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.27
A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res (1997) 1.27
Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev (2001) 1.27
Hormones and prostate cancer: current perspectives and future directions. Prostate (2002) 1.26
Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids (1992) 1.25
Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab (1991) 1.24
CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol (2004) 1.23
Heredity and prostate cancer: a study of World War II veteran twins. Prostate (1997) 1.22
CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res (2004) 1.21
Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev (1999) 1.20
Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate (2006) 1.19
Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer (2003) 1.19
Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res (1998) 1.18
Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab (2007) 1.18
RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res (2006) 1.16
Cancer risk diversity in non-western migrants to Europe: An overview of the literature. Eur J Cancer (2010) 1.16
Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate (2005) 1.15
Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res (2001) 1.15
Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism (2001) 1.15
Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev (2003) 1.15
How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev (2004) 1.15
CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res (1999) 1.14
Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev (2008) 1.14
Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res (1995) 1.14
Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol (1999) 1.13
Studies of genetic factors in prostate cancer in a twin population. J Urol (1994) 1.13
Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics (2001) 1.12
High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer (2004) 1.12
Hereditary prostate cancer: clinical aspects. J Urol (2002) 1.12
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate (2008) 1.11
cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol (2001) 1.11
Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev (1998) 1.11
Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate (2004) 1.11
Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.11
Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev (2000) 1.10
The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. J Hum Genet (2008) 1.10
Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev (2005) 1.09
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer (2011) 1.08
Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology (2001) 1.07
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res (2010) 1.71
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers (2011) 1.56
Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014) 1.55
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res (2010) 1.30
Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol (2005) 1.25
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer (2002) 1.25
Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res (2007) 1.24
Risk assessment of heavy metals in soils and vegetables around non-ferrous metals mining and smelting sites, Baiyin, China. J Environ Sci (China) (2006) 1.12
The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol (2010) 1.07
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res (2013) 1.04
Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy (2012) 1.04
A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma. Cancer Genet Cytogenet (2005) 1.02
Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS One (2011) 0.99
Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. Genes Chromosomes Cancer (2012) 0.98
Rapid high-resolution karyotyping with precise identification of chromosome breakpoints. Genes Chromosomes Cancer (2007) 0.98
Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res (2011) 0.97
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res (2013) 0.96
High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer (2012) 0.96
Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J Androl (2008) 0.94
Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer (2006) 0.93
Heavy metal contamination and source in arid agricultural soil in central Gansu Province, China. J Environ Sci (China) (2008) 0.92
Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis? OMICS (2014) 0.91
Loss of 13q14-q21 and gain of 5p14-pter in the progression of leiomyosarcoma. Mod Pathol (2003) 0.88
Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status. Am J Cancer Res (2012) 0.87
Identification of a neuronal transcription factor network involved in medulloblastoma development. Acta Neuropathol Commun (2013) 0.85
Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). Br J Haematol (2006) 0.85
Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines. Genes Chromosomes Cancer (2008) 0.83
The application of single nucleotide polymorphism microarrays in cancer research. Curr Genomics (2007) 0.83
Comparison of fluid absorption between transurethral enucleation and transurethral resection for benign prostate hyperplasia. Urol Int (2013) 0.83
Celastrol protects kidney against ischemia-reperfusion-induced injury in rats. J Surg Res (2013) 0.83
Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus. Oncogene (2002) 0.83
Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines. Genes Chromosomes Cancer (2005) 0.81
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol (2014) 0.81
The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B. Prostate (2013) 0.80
Cough Test during Tension-Free Vaginal Tape Procedure in Preventing Postoperative Urinary Retention. Adv Urol (2013) 0.78
The pattern of genomic gains in salivary gland MALT lymphomas. Haematologica (2007) 0.78
Identification of a recurrent t(4;6) chromosomal translocation in prostate cancer. J Urol (2007) 0.78
Subtle genomic alterations and genomic instability revealed in diploid cancer cell lines. Cancer Lett (2008) 0.77
The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Cancer Chemother Pharmacol (2009) 0.77
Metastatic potential of lung squamous cell carcinoma associated with HSPC300 through its interaction with WAVE2. Lung Cancer (2009) 0.76
Use of SNPs in cancer predisposition analysis, diagnosis and prognosis: tools and prospects. Expert Opin Med Diagn (2009) 0.75
[Diagnosis and treatment of urethral condyloma acuminatum in male patients]. Zhonghua Nan Ke Xue (2002) 0.75
Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells. Anticancer Drugs (2017) 0.75
[Expression of macrophage migration inhibition factor (MIF) in serum of patients with prostate cancer and its clinical significance]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2011) 0.75
[Progress in researches on stem cell therapy for erectile dysfunction]. Zhonghua Nan Ke Xue (2009) 0.75